QLife (QLIFE) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 increased to KSEK 728 from KSEK 104 year-over-year, driven by a contracted feasibility study with a global pharmaceutical partner.

• Net loss for Q2 2026 was KSEK -4,978, an improvement from KSEK -5,174 in Q2 2025.

• Strategic partnerships in both pharmaceutical and diagnostics sectors advanced, with ongoing feasibility projects and new collaborations.

• Regulatory progress continued, with IVDR certification for Egoo PHE on schedule.

Financial highlights

• Q2 2026 revenue: KSEK 728 (Q2 2025: KSEK 104); H1 2026 revenue: KSEK 750 (H1 2025: KSEK 210).

• EBITDA for Q2 2026: KSEK -4,720 (Q2 2025: KSEK -4,899).

• Net loss for Q2 2026: KSEK -4,978 (Q2 2025: KSEK -5,174).

• Earnings per share for Q2 2026: SEK -0.17 (Q2 2025: SEK -0.62).

• Cash and cash equivalents at end of Q2 2026: KSEK 4,360 (Q2 2025: KSEK 651).

Outlook and guidance

• Priorities for H2 2026 include completing the pharmaceutical feasibility project, expanding partnerships, broadening Egoo platform tests, and progressing IVDR certification.

• Management expresses confidence in future opportunities due to increased partner engagement and regulatory progress.